The global healthcare industry is witnessing a seismic shift from traditional tissue biopsies to non-invasive Liquid Biopsy Platforms. These technologies, centered around the analysis of Circulating Tumor Cells (CTCs), circulating tumor DNA (ctDNA), and exosomes, are revolutionizing early cancer detection and personalized treatment.
From North America to the Asia-Pacific region, medical institutions are prioritizing platforms that offer high sensitivity and specificity. As a leading China Liquid Biopsy Platform Supplier, we integrate the latest in microfluidics and AI-driven data analysis to meet this global demand.
Market Adoption Rate of Automated Liquid Biopsy Systems
Modern platforms no longer focus solely on DNA. The integration of RNA, protein, and epigenetic markers provides a holistic view of the patient's health, leading to more accurate therapeutic decisions.
AI algorithms are now essential for filtering "noise" in sequencing data, allowing for the detection of ultra-low frequency mutations that were previously invisible.
There is a massive push towards miniaturized, portable liquid biopsy devices that can provide rapid results in a clinical or home setting, reducing the reliance on centralized labs.
Ningbo Medvok State-of-the-Art Production Facility
As a premier exporter of diagnostic equipment, our Ningbo facility represents the pinnacle of Chinese biotech innovation. We combine cost-efficiency with uncompromising quality standards (ISO 13485) to deliver world-class liquid biopsy solutions.
Countries Served
Certified Quality
Proprietary Reagents
Technical Support
Monitoring tumor progression and treatment response without the need for invasive surgeries. Ideal for patients who cannot undergo standard biopsies.
Non-Invasive Prenatal Testing (NIPT) uses liquid biopsy principles to screen for genetic abnormalities in fetuses via maternal blood samples.
Accelerating drug development by providing real-time pharmacodynamic markers during clinical trials for new cancer therapies.
Ningbo Medvok Medical Co., Ltd. is a high-tech biotechnology company focused on the R&D and production of antigens, antibodies and downstream detection reagents for diagnosis and therapy. The product pipelines cover cardiovascular and cerebrovascular, inflammation, infectious diseases, tumors, hormones and other categories, from raw materials to finished products.
Innovation is in our DNA! Bioantibody keeps developing new technologies. Currently, our products have been delivered to more than 60 countries and cities worldwide. Using the ISO 13485 management system, the product quality is greatly trusted by customers. With the mission "Biotech For A Better Life", we are committed to innovation and providing our best solutions to our customers. We sincerely believe we could make our special contribution to human ecology and health.
As an IVD solutions provider, we have worked and will keep working intensively to support research and foment knowledge and prevention of the diseases. For us, a well-informed society is a healthier society. We care about protecting the human health and hope all of society to have access to clean, affordable, and reliable biotechnologies.
Furthermore, our economic development will be compatible with proper conduct in relation to ethics, society, the workplace, the environment and respect for human rights. We think of society as a group of individuals with equal rights and opportunities. In order to materialize this commitment, we have developed the sustainability policy on environmental and social matters.
One of the primary challenges in liquid biopsy is the low concentration of target molecules in the blood. Our Biobase China 48 Throughput Automated Sample Processing System (Bk-Pr48) is designed specifically to handle these challenges. By automating the nucleic acid extraction process, we minimize human error and maximize recovery rates of ctDNA.
The transition from lab to industry requires robust scaling. Our Integrated Dac Chromatography Systems provide multi-sample batch purification, which is essential for isolating specific biomarkers or active ingredients in complex biological matrices. These systems are used extensively in herbal extract separation and organic synthesis monitoring.
B2B buyers and global distributors prioritize three things: Regulatory Compliance, Scalability, and Total Cost of Ownership (TCO). Our equipment is built with BPE standard interfaces, making them easy to clean and integrate into existing pharmaceutical diagnostic reagent preparation workflows. Whether you are a lab in Germany or a hospital group in Brazil, our platforms are designed for seamless global deployment.
Medvok Medical
